Complejo Hospitalario Universitario Insular Materno Infantil

The Complejo Hospitalario Universitario Insular Materno Infantil is actively investigating new treatments for blood‑related cancers such as acute myeloid leukemia, acute lymphoblastic leukemia and diffuse large B‑cell lymphoma, with the goal of improving survival rates and reducing disease recurrence.

• Targeted kinase inhibitors for high‑risk AML
• Antibody‑drug conjugates in refractory lymphoma
• MRD‑guided therapeutic strategies in pediatric ALL
• Combination immunotherapy approaches for relapsed disease
• Optimized pediatric leukemia protocols

Collaborative networks across Europe support these studies, fostering rapid translation of laboratory discoveries into clinical practice.

A broad portfolio of trials focuses on non‑small cell lung cancer and small cell lung cancer, evaluating innovative immunotherapy combinations and precision‑targeted agents for mutations such as EGFR, KRAS and ALK.

• PD‑L1 checkpoint inhibitors as adjuvant therapy after resection
• KRAS G12C inhibitors for metastatic disease
• EGFR‑mutant specific tyrosine‑kinase inhibitors
• Neoadjuvant chemo‑immunotherapy regimens
• Biomarker‑driven patient selection for novel agents

The aim is to extend progression‑free survival and offer personalized treatment pathways for lung cancer patients.

Research at the site includes studies on triple‑negative breast cancer, HER2‑positive breast cancer, as well as ovarian and endometrial cancers, seeking to integrate targeted therapies and novel antibody‑drug conjugates into standard care.

• PARP inhibitors for BRCA‑mutated breast cancer
• HER2‑directed antibody‑drug conjugates in advanced disease
• Combination endocrine therapy with CDK4/6 inhibitors
• Adjuvant immunotherapy for high‑risk early‑stage breast cancer
• Maintenance strategies for recurrent ovarian cancer

These trials aim to increase disease‑free survival and provide new options for patients with limited treatment choices.

The hospital conducts several investigations into muscle‑invasive bladder cancer and upper‑tract urothelial carcinoma, testing immunotherapeutic and targeted approaches to improve outcomes while preserving organ function.

• Neoadjuvant checkpoint inhibitor trials
• HER2‑targeted antibody‑drug conjugates for urothelial carcinoma
• Bladder‑preserving chemoradiotherapy regimens
• Biomarker studies to predict response to immunotherapy
• Renal function monitoring during cisplatin‑based treatment

The focus is on achieving higher complete‑response rates and reducing the need for radical surgery.

Trials address atherosclerotic cardiovascular disease, elevated lipoprotein(a) levels, and type 1 diabetes, aiming to prevent disease progression and evaluate novel therapeutic agents.

• Lp(a)‑lowering RNA therapeutics
• Beta‑blocker and antiplatelet regimen for spontaneous coronary artery dissection
• Metformin adjunct therapy in hormone‑sensitive breast cancer
• Fluid resuscitation strategies for acute pancreatitis
• Immune‑modulating approaches to preserve beta‑cell function

These studies seek to reduce cardiovascular events and improve metabolic control in at‑risk populations.

Dedicated pediatric programs explore treatments for childhood cancers and neonatal conditions, including preterm infants with intestinal malabsorption and various forms of leukemia.

• Optimized enteral feeding protocols for preterm neonates
• FLT3‑ITD targeted therapy in pediatric AML
• Imatinib‑based regimens for Ph+ acute lymphoblastic leukemia
• Lymphoblastic lymphoma treatment intensification
• Safety and efficacy assessments of novel agents in children

The objective is to enhance survival while minimizing long‑term treatment toxicity for young patients.